Elicio TherapeuticsELTX
13F holders, Q4 2024 (December 31)17holders −1
1new positions
3sold out
$4.97avg. 13F price*
At the end of Q4 2024, 17 institutions reported holding Elicio Therapeutics Inc. (ELTX) in their 13F filings, down 1 from Q3 2024. 1 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($1.2M), Geode Capital Management, LLC ($347K) and CM Management, LLC ($204K).
- Company
- Elicio Therapeutics Inc.
- CUSIP
- 28657F103
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $332 |
| Exits | 3 | $132K |
All 13F filers, Q3 2024 → Q4 2024: 744 shares bought and 38,228 shares sold, net −37,484 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Vanguard Group Inc. | 0.00% | Add +0.2% | 245,823 | $1.2M |
| Geode Capital Management, LLC | 0.00% | Reduce -1.2% | 70,721 | $347K |
| CM Management, LLC | 0.18% | Reduce -20.0% | 40,000 | $204K |
| Northern Trust Corp. | 0.00% | No change | 30,769 | $157K |
| State Street Corp. | 0.00% | No change | 21,900 | $107K |
| BlackRock, Inc. | 0.00% | Add +0.6% | 19,811 | $101K |
| Meyer Handelman Co. | 0.00% | No change | 13,899 | $71K |
| CIBC Private Wealth Group LLC | 0.00% | No change | 7,000 | $43K |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 1,554 | $8K |
| Bank of America Corp. | 0.00% | Reduce -3.2% | 1,197 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -35.7% | 611 | $3K |
| Citigroup Inc. | 0.00% | No change | 374 | $2K |
| Morgan Stanley | 0.00% | Reduce -4.2% | 230 | $1K |
| SBI Securities Co., Ltd. | 0.00% | — | 83 | $423 |
| BNP Paribas Financial Markets | 0.00% | New | 65 | $332 |
| JPMorgan Chase & Co. | 0.00% | No change | 18 | $88 |
| UBS Group AG | 0.00% | Reduce -98.0% | 17 | $87 |
"% of holder's portfolio" is ELTX's weight in each manager's 13F, not the share of Elicio Therapeutics Inc. the manager owns.